Important Update For CEL-SCI Corporation Annual Meeting of Shareholders
April 08 2020 - 8:00AM
Business Wire
CEL-SCI Corporation (NYSE American: CVM), announced today
that there are now two options to access the virtual meeting
webcast. You may join as a “Guest” or join as a “Shareholder”. If
you join as a “Shareholder” you will be required to have a control
number and password. The password for the meeting is
CVM2020. However, you may join as a “Guest” without a
control number and password. The 2020 Annual Meeting will still be
held on April 17, 2020 at 10:30 a.m. ET and access to the webcast
online is available at http://www.meetingcenter.io/291292248.
We encourage you to attend the annual meeting via the webcast
due to the governmental restrictions placed on public meetings.
Geert Kersten, the Company’s Chief Executive Officer, will be
presiding at the annual meeting and expects to answer questions
submitted by shareholders.
About CEL-SCI Corporation
CEL-SCI is a clinical-stage biotechnology company focused on
finding the best way to activate the immune system to fight cancer
and infectious diseases. The Company’s lead investigational therapy
Multikine is currently in a pivotal Phase 3 clinical trial
involving head and neck cancer, for which the Company has received
Orphan Drug Status from the FDA. The Company’s LEAPS technology is
being developed for rheumatoid arthritis and as a potential
treatment of COVID-19 in hospitalized patients. The Company has
operations in Vienna, Virginia, and near Baltimore, Maryland.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended, including statements with respect to Multikine and the
Phase 3 clinical trial of Multikine in patients with advanced
primary squamous cell carcinoma of the head and neck. When used in
this press release, the words "intends," "believes," "anticipated,"
"plans" and "expects," and similar expressions, are intended to
identify forward-looking statements. Such statements are subject to
risks and uncertainties that could cause actual results to differ
materially from those projected. Factors that could cause or
contribute to such differences include, an inability to duplicate
the clinical trials or nonclinical results demonstrated in clinical
studies, timely development of any potential products that can be
shown to be safe and effective, receiving necessary regulatory
approvals, difficulties in manufacturing any of the Company's
potential products, inability to raise the necessary capital and
the risk factors set forth from time to time in CEL-SCI's filings
with the Securities and Exchange Commission, including but not
limited to its report on Form 10-K/A for the year ended September
30, 2019. The Company undertakes no obligation to publicly release
the result of any revision to these forward-looking statements
which may be made to reflect the events or circumstances after the
date hereof or to reflect the occurrence of unanticipated
events.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200408005113/en/
Gavin de Windt CEL-SCI Corporation (703) 506-9460
Cel Sci (AMEX:CVM)
Historical Stock Chart
From Aug 2024 to Sep 2024
Cel Sci (AMEX:CVM)
Historical Stock Chart
From Sep 2023 to Sep 2024